Search

Introduction Gestational anaemia, which has specific haemoglobin (Hb) reference values in each trimester of gestation, increases the risk of maternal mortality and complications both in pregnancy and in the first months of the newborn's life. The objective of this study is to evaluate haemoglobin levels in pregnant women in our population, to determine the prevalence of gestational anaemia and to propose reference values specific to them. Material and methods Retrospective study of all blood counts requested in pregnancy and postpartum controls during 2019. Results 9995 gestation haemograms corresponding to 5507 pregnant women were reviewed. Of these, 1134 patients underwent complete follow-up in 2019. The prevalence data for anaemia were 1.8%, 11.8% and 13.2% in each trimester respectively, and the global prevalence in pregnancy was 22.6%. Regarding postpartum anaemia, its prevalence with respect to all pregnant women was 2.99%, increasing to 38.2% in those patients with complications during delivery. Conclusions The prevalence of gestational anaemia in our population is somewhat higher than in countries like ours. Therefore, there is room for improvement in our current clinical protocols. It is important to assess updating analytical controls with other more adequate parameters to determine iron reserves, as this is the main cause of anaemia.

Resumen Antecedentes y objetivos Los programas de Patient blood management (PBM) han demostrado su valor en la mejora continua de la practica asistencial, gracias a la revision sistematica de resultados y a su actualizacion dinamica y multidisciplinar, de acuerdo con las nuevas evidencias clinicas. Nuestro objetivo es demostrar la efectividad y seguridad de protocolos sencillos, aplicables en hospitales de segundo nivel. Pacientes y metodos Se han analizado retrospectivamente 702 pacientes intervenidos de artroplastia programada desde 2011 hasta 2018. Durante este periodo se ha registrado en la historia clinica de los pacientes la evolucion transfusional y el manejo de la anemia y el sangrado. Resultados Fases y tasas de transfusion: ano 2011-2012 «Programa autodonacion universal»: 62,4%; ano 2013 «inicio optimizacion de hemoglobina preoperatoria y retirada autodonacion universal» 22,5%; ano 2015 «suspension del uso de recuperadores y los drenajes» 13,2%; y ano 2017 «inicio de uso de acido tranexamico (ATX)» 3,6%. Se ha conseguido una reduccion significativa de la tasa y el numero de concentrados de hematies transfundidos (p Conclusion Un programa PBM sencillo, progresivo y multidisciplinar, con reevaluacion continuada, ha permitido reducir la transfusion y la estancia media hospitalaria en un hospital de segundo nivel.

Resumen Introduccion La infeccion por SARS-CoV-2 presenta gran heterogeneidad clinica, desde asintomatica hasta cuadros clinicos graves con un desenlace fatal. Algunos autores refieren el grupo sanguineo ABO como posible marcador biologico de susceptibilidad para la enfermedad. Pacientes y metodos Se ha recogido a los pacientes ingresados con infeccion por COVID-19 y se ha analizado la incidencia por grupos en relacion con la base poblacional de la Comunidad Foral de Navarra, asi como sus principales complicaciones y evolucion. Resultados Los pacientes de grupo O ingresados con infeccion por COVID-19 son proporcionalmente menos respecto a la base poblacional, sin ser la diferencia estadisticamente significativa. Los grupos AB y B son un 38% mas en el grupo de infectados que en la poblacion. El grupo B ha presentado significacion estadistica en cuanto al numero de complicaciones tromboticas junto con mayor tasa de ingreso en unidades de Cuidados Intensivos. Conclusion El estudio sugiere menor susceptibilidad a la infeccion de los pacientes de grupos O y mayor riesgo de complicaciones en el grupo B. Hacen falta estudios con mayor tamano muestral para poder obtener resultados significativos.

The "Patient Blood Management" (PBM) programmes have demonstrated their value in the continuous improvement of care practice, due to continuous systematic reviewing of results and their dynamic and multidisciplinary updating in accordance with new clinical evidence. Our goal is to demonstrate the effectiveness of simple protocols, applicable in second level hospitals.702 patients undergoing scheduled arthroplasty from 2011 to 2018 were retrospectively analysed. During this period, the evolution of transfusion rates and anaemia and bleeding management were recorded in the patients' computerised clinical histories.Stages and transfusion rates were: Year 2011-2012, "Universal self-donation programme": 62.4%; year 2013, "Optimization of preoperative haemoglobin and universal self-donation withdrawal", 22.5%; year 2015, "Stopping the use of cell-savers and drains", 13.2%; and year 2017, "Introduction of routine tranexamic acid", 3.6%. A significant reduction in the transfusion rate and volume (P.001) and the average hospital stay (8 to 6 days) (P.001) was achieved. In multivariate models, transfused patients have a .5-day stay and there is a trend towards a reduction in complications, being fewer in patients receiving tranexamic acid (OR .44).A simple progressive and multidisciplinary PBM programme, with continued re-evaluation, has allowed a reduction in transfusion rates and average hospital stay.